Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts
暂无分享,去创建一个
H. Kalthoff | J. Egberts | T. Becker | N. Heits | F. Braun | A. Bernsmeier | C. Hauser | Tillmann Heinze | Jannik Kerber | T. Heinze
[1] T. Fujimori,et al. IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling , 2014, British Journal of Cancer.
[2] C. Porta,et al. Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..
[3] Craig E. Higgins,et al. SERPINE1: A Molecular Switch in the Proliferation-Migration Dichotomy in Wound-"Activated" Keratinocytes. , 2014, Advances in wound care.
[4] J. She,et al. Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of mycophenolic acid. , 2013, International journal of clinical and experimental pathology.
[5] Y. Woo,et al. Cancer-Associated Fibroblasts Promote Proliferation of Endometrial Cancer Cells , 2013, PloS one.
[6] G. Gores,et al. Liver Transplantation for Perihilar Cholangiocarcinoma , 2013, Digestive Diseases.
[7] U. Neumann,et al. Liver transplantation for intra- and extrahepatic cholangiocarcinoma. , 2013, Annals of transplantation.
[8] F. Jerhammar,et al. Cancer-Associated Fibroblasts Induce Matrix Metalloproteinase–Mediated Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cells , 2012, Molecular Cancer Research.
[9] R. Puri,et al. IL‐13 regulates cancer invasion and metastasis through IL‐13Rα2 via ERK/AP‐1 pathway in mouse model of human ovarian cancer , 2012, International journal of cancer.
[10] W. V. van IJcken,et al. Metabolic enzyme IMPDH is also a transcription factor regulated by cellular state. , 2012, Molecular cell.
[11] J. Casal,et al. High expression of IL-13 receptor α2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. , 2012, Cancer research.
[12] H. Lenz,et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis , 2012, British Journal of Cancer.
[13] Y. Zhang,et al. Interleukin-8 induces the endothelial cell migration through the Rac 1/RhoA-p38MAPK pathway. , 2012, European review for medical and pharmacological sciences.
[14] J. Darnell,et al. The JAK-STAT pathway at twenty. , 2012, Immunity.
[15] O. Franco,et al. Targeting the tumor stroma as a novel therapeutic approach for prostate cancer. , 2012, Advances in pharmacology.
[16] A. Mintz,et al. IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. , 2011, Translational oncology.
[17] Z. Mujagic,et al. Interleukin 13 expression in the primary breast cancer tumour tissue. , 2011, Biochemia medica.
[18] D. Stocken,et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 , 2011, Cancer Immunology, Immunotherapy.
[19] S. Brandt,et al. Induction of TLR-2 and TLR-5 Expression by Helicobacter pylori Switches cagPAI-Dependent Signalling Leading to the Secretion of IL-8 and TNF-α , 2011, PloS one.
[20] J. Dufour,et al. Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma , 2011, Molecular Cancer Therapeutics.
[21] T. Ishiko,et al. Hepatic Stellate Cells Accelerate the Malignant Behavior of Cholangiocarcinoma Cells , 2011, Annals of Surgical Oncology.
[22] Robert A. Weinberg,et al. Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts , 2010, Proceedings of the National Academy of Sciences.
[23] M. Acalovschi,et al. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. , 2010, Journal of gastrointestinal and liver diseases : JGLD.
[24] S. Donnelly,et al. Inflammation and cancer: macrophage migration inhibitory factor (MIF)—the potential missing link , 2010, QJM : monthly journal of the Association of Physicians.
[25] J. Fellenberg,et al. Overexpression of Inosine 5′-Monophosphate Dehydrogenase Type II Mediates Chemoresistance to Human Osteosarcoma Cells , 2010, PloS one.
[26] Hai-rim Shin,et al. Epidemiology of cholangiocarcinoma: An update focusing on risk factors , 2010, Cancer science.
[27] A. Sutton,et al. Monocyte chemoattractant protein‐1 (MCP‐1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells , 2009, International journal of cancer.
[28] Fei Xing,et al. Cancer associated fibroblasts (CAFs) in tumor microenvironment. , 2010, Frontiers in bioscience.
[29] Y. Abiko,et al. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker , 2010, Molecular Cancer.
[30] Hua Yu,et al. STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.
[31] M. Miyazaki,et al. Stromal MCP‐1 in mammary tumors induces tumor‐associated macrophage infiltration and contributes to tumor progression , 2009, International journal of cancer.
[32] S. Ishikawa,et al. Hepatic Stellate Cells May Relate to Progression of Intrahepatic Cholangiocarcinoma , 2009, Annals of Surgical Oncology.
[33] T. Suthiphongchai,et al. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. , 2009, Oncology reports.
[34] T. Okada,et al. Rapamycin inhibits growth of cholangiocarcinoma cells. , 2009, Hepato-gastroenterology.
[35] Derek Y. Chiang,et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.
[36] W. Ansorge,et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid , 2008, Molecular Cancer Therapeutics.
[37] M. Dai,et al. Mycophenolic Acid Activation of p53 Requires Ribosomal Proteins L5 and L11* , 2008, Journal of Biological Chemistry.
[38] Douglas B. Evans,et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.
[39] M. Andersson,et al. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer , 2008, International Journal of Clinical Oncology.
[40] G. Gores,et al. Cholangiocarcinoma: is transplantation an option? For whom? , 2007, Journal of hepatology.
[41] L. Bernd,et al. Prognostic significance of drug-regulated genes in high-grade osteosarcoma , 2007, Modern Pathology.
[42] J. Járay,et al. Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. , 2007, Leukemia research.
[43] J. Bernhagen,et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.
[44] F. Luppia,et al. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation , 2007 .
[45] A. Mehrabi,et al. Antifibrotic actions of mycophenolic acid , 2006, Clinical transplantation.
[46] G. Kroemer,et al. Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.
[47] J. Shaughnessy,et al. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells , 2006, Molecular Cancer Therapeutics.
[48] A. Allison. Mechanisms of action of mycophenolate mofetil , 2005, Lupus.
[49] Jeremy J. W. Chen,et al. The role of interleukin-8 in cancer cells and microenvironment interaction. , 2005, Frontiers in bioscience : a journal and virtual library.
[50] D. Jonas,et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy , 2005, BMC Cancer.
[51] N. Sonenberg,et al. Upstream and downstream of mTOR. , 2004, Genes & development.
[52] M. O. Moraes,et al. Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine. , 2004, Transplantation proceedings.
[53] R. Abraham. mTOR as a positive regulator of tumor cell responses to hypoxia. , 2004, Current topics in microbiology and immunology.
[54] M. Manns,et al. Clinical Pharmacokinetics of Everolimus , 2004, Clinical pharmacokinetics.
[55] K. Shuai,et al. Regulation of JAK–STAT signalling in the immune system , 2003, Nature Reviews Immunology.
[56] Michael Bacher,et al. Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma , 2003, International journal of cancer.
[57] John David,et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[58] M. Gonen,et al. Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma , 2001, Annals of surgery.
[59] E. Jaurrieta,et al. Changing strategies in diagnosis and management of hilar cholangiocarcinoma , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[60] E. Jaurrieta,et al. Changing strategies in diagnosis and management of hilar cholangiocarcinoma , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[61] J. Martorell.,et al. Assessment of mycophenolic acid-induced immunosuppression: a new approach. , 2000, Clinical chemistry.
[62] A. Allison,et al. Mycophenolate mofetil and its mechanisms of action. , 2000, Immunopharmacology.
[63] G. Gores,et al. Prolonged disease‐free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[64] T. Seufferlein,et al. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. , 1999, Cancer research.
[65] J. Hickman,et al. Cell cycle specific induction of HL-60 cell differentiation and apoptosis by mycophenolic acid , 1997, Cell Death and Differentiation.
[66] K. Matsumoto,et al. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. , 1997, Cancer research.
[67] M. Schreier,et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.
[68] K. Schupak,et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy , 1995, The British journal of surgery.
[69] R. Tressler,et al. Anti‐tumor activity of mycophenolate mofetil against human and mouse tumors in vivo , 1994, International journal of cancer.
[70] G. Cunha,et al. Role of stroma in oestrogen-induced epithelial proliferation. , 1992, Epithelial cell biology.
[71] M. Gleave,et al. Human prostate cancer model: Roles of growth factors and extracellular matrices , 1992, Journal of cellular biochemistry. Supplement.